Nemaura Medical, Inc. · OTC:NMRD

Nemaura Medical — Technical Presentation (December 2018)

11 slides from Nemaura Medical's technical presentation, Dec 18, 2018

  1. Slide 1: Better Diagnostics for Life: Clinical Presentation sugarBEAT

    NASDAQ: NMRD Better Diagnostics for Life Clinical Presentation sugarBEAT® 18th December 2018

  2. Slide 2: A Prospective Single Centre Evaluation of the Accuracy and Safety of sugarBEAT

    A Prospective Single Centre Evaluation of the Accuracy and safety of the sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System Dr T Rahman, MBBS, PhD Clinical research Manager, Nemaura Medical Inc., 2

  3. Slide 3: Study Objective

    Study Objective A EU based study to determine the safety and accuracy of the sugarBEAT® CGM for FDA De Novo submission 3

  4. Slide 4: Study Design

    Study Design ❖Prospective single arm, single centre study ❖Accuracy and safety assessed over 7 consecutive wear days, consisting of 3 non-consecutive in-clinic visits, and 4 home wear days. ❖Venous blood samples used as reference for in-clinic portion of study using Architect c8000 ❖Abbott Freestyle

  5. Slide 5: Study Methods

    Study Methods ❖>25 subjects enrolled for screening at each of 3 stages ❖25 subjects selected after screening in each stage, with approximately equal split between Type 1 and Type 2 ❖No subjects lost due to drop out ❖All 25 subjects completed 2 days home study and 3 days in- clinic study ❖12 of each

  6. Slide 6: Accuracy vs Glucose Range In-clinic 1-point calibration

    Accuracy vs Glucose Range In-clinic 1-point calibration The proportion of agreement is 76.098% (with 95% confidence interval from 0.75382 to 0.76814). Table 1. shows the proportion of agreement broken down for different glucose and accuracy ranges and MARD / MAD. MARD +/-20% or +/- 20mg/dL (76% of p

  7. Slide 7: Accuracy vs Glucose Range In-clinic 1-point calibration

    Accuracy vs Glucose Range In-clinic 1-point calibration MAD: Mean Absolute Deviation MARD: Mean Absolute Relative Deviation The performance evaluation included the proportion of the CGM system values that are within ±10 to >40% of relative difference of reference value at glucose levels >80 mg/dL an

  8. Slide 8: Accuracy vs Glucose Range In-clinic 2-point Calibration

    Accuracy vs Glucose Range In-clinic 2-point Calibration The proportion of agreement is 78.33% (with 95% confidence interval from 0.77646 to 0.79032). Table 1. shows the proportion of agreement broken down for different glucose and accuracy ranges and MARD / MAD. MARD +/- 20% or +/- 20mg/dL (78.7% of

  9. Slide 9: Accuracy vs Glucose Range In-clinic 2-point Calibration

    Accuracy vs Glucose Range In-clinic 2-point Calibration MAD: Mean Absolute Deviation MARD: Mean Absolute Relative Deviation Note 1: Number of paired points is different/higher compared 1-point calibration in light of better accuracy leading to more data points falling within the 40-400mg/dL range Th

  10. Slide 10: Safety Evaluation

    Safety Evaluation Previous studies: >100 Patient days wear time – No major adverse events or skin irritation reported. >525 Patient days wear time – No major adverse events or skin irritation reported. Current study: >250 Patient days to date with no device related adverse events or skin irritation

  11. Slide 11: Conclusion

    Conclusion The analysis indicates the in-clinic portion of the study shows accuracy levels, as measured using overall nominal MARD, as comparable to previously reported data and within the targets for the intended indications. 11

Nemaura Medical — Technical Presentation (December 2018) on 6ix